Advertisement

Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)

Published:September 28, 2009DOI:https://doi.org/10.1016/j.amjcard.2009.07.002
      It remains unclear whether dual antiplatelet therapy >12 months might carry a better prognosis after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). To address the hypothesis that in the real world the risk of very late thrombosis after PCI with DESs can be decreased by an extended use of clopidogrel, we set up the Two-Year ClOpidOgrel Need (TYCOON) registry and prospectively investigated the impact on very late thrombosis of 12- versus 24-month dual antiplatelet regimens in an unselected population. The registry enrolled 897 consecutive patients who underwent PCI with stenting from January 1, 2003, to December 31, 2004, and had dual antiplatelet therapy. All patients had a 4-year clinical follow-up. In the 447 patients with DES implantation, the dual antiplatelet regimen after PCI was given for 12 months in the 173 patients treated in 2003 (12-month group) and for 24 months in the 274 patients treated in 2004 (24-month group). Comparison between groups did not reveal any significant difference in baseline clinical characteristics, angiographic and procedural features, and major adverse cardiac events. During follow-up, there were 5 cases of stent thrombosis after PCI in the 12-month DES group and 1 case in the 24-month DES group (p = 0.02). Specifically, there were 2 cases of subacute thrombosis (1 in each group), no case of late thrombosis, and 4 cases of very late thrombosis occurring at 13, 15, 17, and 23 months after DES implantation in the 12-month group only. In conclusion, a 2-year dual antiplatelet regimen with aspirin and clopidogrel can prevent the occurrence of very late stent thrombosis after PCI with DESs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • King III, S.B.
        • Smith Jr, S.C.
        • Hirshfeld Jr, J.W.
        • Jacobs A.K.
        • Morrison D.A.
        • Williams D.O.
        • Feldman T.E.
        • Kern M.J.
        • O'Neill W.W.
        • Schaff H.V.
        • Whitlow P.L.
        • Adams C.D.
        • Anderson J.L.
        • Buller C.E.
        • Ceager M.A.
        • Ettanger S.M.
        • Halperin J.L.
        • Hunt S.A.
        • Krumholz H.M.
        • Kushner F.G.
        • Lytle B.W.
        • Nishimura R.
        • Page R.L.
        • Riegel B.
        • Tarkington L.G.
        • Yancy C.W.
        • ACC/AHA/SCAI
        2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines.
        J Am Coll Cardiol. 2008; 51: 172-209
        • Banerjee S.
        • Varghese C.
        • Samule J.
        • Banerjee S.
        • Varghese C.
        • Samuel J.
        • Weideman R.A.
        • Little B.B.
        • Kelly K.C.
        • Rao S.V.
        • Reilly R.F.
        • Brilakis E.S.
        Comparison of the impact of short (<1 year) and long term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality.
        Am J Cardiol. 2008; 102: 1159-1162
        • Butler M.J.
        • Eccleston D.
        • Clark D.J.
        • Butler M.J.
        • Eccleston D.
        • Clark D.J.
        • Ajani A.E.
        • Andrianopoulos N.
        • Brennan A.
        • New G.
        • Black A.
        • Szto G.
        • Reid C.M.
        • Yan B.P.
        • Shaw J.A.
        • Dart A.M.
        • Duffy S.J.
        • Melbourne Interventional Group
        The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
        Am Heart J. 2009; 157: 899-907
        • Maisel W.H.
        Unanswered questions; drug-eluting stents and the risk of late thrombosis.
        N Engl J Med. 2007; 356: 981-984
        • Marzocchi A.
        • Saia F.
        • Piovaccari G.
        • Manari A.
        • Aurier E.
        • Benassi A.
        • Cremonesi A.
        • Percoco G.
        • Varani E.
        • Magnavacchi P.
        • Guastaroba P.
        • Grilli R.
        • Maresta A.
        Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
        Circulation. 2007; 115: 3181-3188
        • Liistro F.
        • Colombo A.
        Late acute thrombosis after paclitaxel eluting stent implantation.
        Heart. 2001; 86: 262-264
        • Kerner A.
        • Gruberg L.
        • Kapeliovich M.
        • Grenadier E.
        Late stent thrombosis after implantation of a sirolimus-eluting stent.
        Catheter Cardiovasc Interv. 2003; 60: 505-508
        • Pasceri V.
        • Pelliccia F.
        • Cianfrocca C.
        • Pristipino C.
        • Santini M.
        • Richichi G.
        Very late thrombosis after sirolimus-eluting stent implantation.
        J Cardiovasc Med. 2006; 7: 438-442
        • Biondi-Zoccai G.G.
        • Lotrionte M.
        • Agostoni P.
        • Abbate A.
        • Fusaro M.
        • Burzotta F.
        • Testa L.
        • Sheiban I.
        • Sangiorgi G.
        A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease.
        Eur Heart J. 2006; 27: 2667-2674
        • Mauri L.
        • Hsieh W.H.
        • Massaro J.M.
        • Ho K.K.
        • D'Agostino R.
        • Cutlip D.E.
        Stent thrombosis in randomized clinical trials of drug-eluting stents.
        N Engl J Med. 2007; 356: 1020-1029
        • Alpert J.S.
        • Thygesen K.
        • Antman E.
        • Bassand J.P.
        Myocardial infarction redefined: a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction.
        J Am Coll Cardiol. 2000; 36: 959-969
        • Eisenstein E.L.
        • Anstrom K.J.
        • Kong D.F.
        • Shaw L.K.
        • Tuttle R.H.
        • Mark D.B.
        • Kramer J.M.
        • Harrington R.A.
        • Matchar D.B.
        • Kandzari D.E.
        • Peterson E.D.
        • Schulman K.A.
        • Califf R.M.
        Clopidogrel use and long-term clinical outcome after drug-eluting stent implantation.
        JAMA. 2007; 297: 159-168
        • Beohar N.
        • Davidson C.J.
        • Kip K.E.
        • Goodreau L.
        • Vlachos H.A.
        • Meyers S.N.
        • Benzuly K.H.
        • Flaherty J.D.
        • Ricciardi M.J.
        • Bennett C.L.
        • Williams D.O.
        Outcomes and complications associated with off-label and untested use of drug-eluting stents.
        JAMA. 2007; 297: 1992-2000
        • Doyle B.
        • Rihal C.S.
        • O'Sullivan C.J.
        • Lennon R.J.
        • Wiste H.J.
        • Bell M.
        • Bresnahan J.
        • Holmes Jr, D.R.
        Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents.
        Circulation. 2007; 116: 2391-2398
        • Choi S.-H.
        • Prasad A.
        • Tsimikas S.
        The evolution of thienopyridine therapy.
        J Am Coll Cardiol. 2008; 51: 2228-2229
        • Iakovou I.
        • Schmidt T.
        • Bonizzoni E.
        • Ge L.
        • Sangiorgi G.M.
        • Stankovic G.
        • Airoldk F.
        • Chieffo A.
        • Montorfano M.
        • Carlino M.
        • Michev I.
        • Corvaja N.
        • Briguori C.
        • Gerckens U.
        • Grube E.
        • Colombo A.
        Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluding stents.
        JAMA. 2005; 293: 2126-2130
        • Roy P.
        • Bonello L.
        • Torguson R.
        • Okabe T.
        • Pinto Slottow T.L.
        • Steinberg D.H.
        • Kaneshige K.
        • Xue Z.
        • Satler L.F.
        • Kent K.M.
        • Suddath W.O.
        • Pichard A.D.
        • Lindsay J.
        • Waksman R.
        Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
        Am J Cardiol. 2009; 103: 801-805
        • Park D.W.
        • Yun S.C.
        • Lee S.W.
        • Kim Y.H.
        • Lee C.W.
        • Hong M.K.
        • Cheong S.S.
        • Kim J.J.
        • Park S.W.
        • Park S.J.
        Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents.
        J Am Coll Cardiol Intv. 2008; 1: 494-503
        • Pfistaer M.
        • Brunner-La Rocca H.P.
        • Buser P.T.
        • Rickenbacher P.
        • Hunziker P.
        • Mueller C.
        • JEger R.
        • Bader F.
        • Osswald S.
        • Kaiser C.
        • BASKET-LATE Investigators
        Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
        J Am Coll Cardiol. 2006; 48: 2584-2591
        • Spertus J.A.
        • Kettelkamp R.
        • Vance C.
        • Decker B.
        • Jones P.G.
        • Rumsfeld J.S.
        • Messenger J.C.
        • Khanal S.
        • Peterson E.D.
        • Bach R.G.
        • Krumholz H.M.
        • Cohun D.J.
        Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER Registry.
        Circulation. 2006; 113: 2803-2809
        • Dean J.
        • Yujie Z.
        • Yingxin Z.
        • Yuyang L.
        • Yonghe G.
        • Wanjun C.
        • Zheng C.
        Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
        Clin Cardiol. 2009; 32: 164-168
        • Angiolillo D.J.
        Variability in responsiveness to oral antiplatelet therapy.
        Am J Cardiol. 2009; 103: 27A-34A